Clincosm LogoSign in Get a demo

Phase I Comparative Bioavailability Study

Sponsor
AstraZeneca (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT00777582
Collaborator
(none)
197
Enrollment
10
Locations
3
Arms
170.1
Anticipated Duration (Months)
19.7
Patients Per Site
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this phase I randomised cross over study is to determine and compare the bioavailability of two different oral formulations of AZD2281 in advanced solid tumour cancer patients

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
197 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
A Phase I, Randomised, 2 Period Cross Over Study to Determine the Comparative Bioavailability of Two Different Oral Formulations of AZD2281 in Cancer Patients With Advanced Solid Tumours
Actual Study Start Date :
Oct 27, 2008
Actual Primary Completion Date :
Feb 6, 2009
Anticipated Study Completion Date :
Dec 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment A

300mg bid (twice daily) tablet dose

Drug: AZD2281
Oral single dose formulation
Other Names:
  • Olaparib

    		•
    Experimental: Treatment B

    400 mg twice daily (bid) capsule dose

    Drug: AZD2281
    Oral single dose formulation
    Other Names:
  • Olaparib

    		•
    Experimental: Treatment C

    400mg bid (twice daily) tablet dose

    Drug: AZD2281
    Oral single dose formulation
    Other Names:
  • Olaparib

    		•

    Outcome Measures

    Primary Outcome Measures

    1. PK Phase Primary Outcome: To determine the comparative bioavailability of a new tablet formulation of AZD2281 compared to the existing capsule formulation [Blood samples (12) will be taken at pre-defined intervals following dosing of a single capsule and a single tablet dose]

    2. Continued Supply Phase: To enable patients to continue to receive treatment with AZD2281. Safety and tolerability data will be collected to further determine the safety and tolerability of the capsule formulation of AZD2281 in these patients [every 28 days]

    3. Continued Supply Expansion Phase: To compare the safety and tolerability of the tablet and capsule formulation of AZD2281 in all patients: Safety, AEs, Physical Exam, vital signs [at every visit]

    4. Dose Escalation Phase of continued supply expansion: To determine safety & tolerability of higher than 200mg bid (to 400mg) of tablet & compare safety & tolerability profile of tablet with 400mg capsule [at every visit]

    5. Randomised tablet formulation continued supply expansion phase (Group 8): To determine the safety and tolerability profile of selected tablet dose schedules of the melt-extrusion (tablet) formulation. [at every visit]

    Secondary Outcome Measures

    1. PK Phase Secondary Outcome: To generate single dose PK data for the new tablet formulation in man, and to generate information on dose linearity for the new tablet formulation [Blood samples (12) will be taken at pre-defined intervals prior to and following dosing of a single capsule and a single tablet dose]

    2. To compare the extent of PARP inhibition achieved in peripheral blood mononuclear cells (PBMCs) following dosing of both the new tablet formulation and existing capsule formulation [Blood samples (4) will be taken at pre-defined intervals prior to and following dosing of a single capsule and a single tablet dose]

    3. To determine the safety and tolerability of AZD2281 for both the new tablet formulation and existing capsule formulations [every 28 days]

    4. Continued Supply Expansion Phase: To compare the steady state exposure achieved with 200mg bid tablet formulation and 400mg bid capsule formulation [at visit 3 and visit 4]

    5. Continued Supply Expansion Phase: To describe the efficacy data observed in patients treated with the capsule and the tablet [RECIST, Progression Free Survival, Best overall response and CA-125 response]

    6. Dose Escalation Phase of the continued supply expansion: To determine the single dose and steady state exposures achieved with higher doses of AZD2281 tablet formulation [at every visit]

    7. Dose Escalation Phase of the continued supply expansion: To compare between patients the single dose and steady state exposures of AZD2281 achieved with selected tablet doses and the 400mg bid capsule dose [at every visit]

    8. Dose Escalation Phase of the continued supply expansion: To describe the efficacy data observed in patients treated with the capsule formulation and the tablet formulation [at every visit]

    9. Randomised tablet formulation continued supply expansion phase (Group 8): To determine the single dose and steady state exposures achieved with the selected table dose schedules of AZD2281 melt-extrusion (tablet) formulation [at every visit]

    10. Randomised tablet formulation continued supply expansion phase (Group 8): To obtain a preliminary assessment of the effect of food on the exposure to AZD2281 following dosing of the melt-extrusion (tablet) formulation. [at every visit]

    11. Randomised tablet formulation continued supply expansion phase (Group 8): To describe the efficacy data observed in patients treated with the melt-extrusion (tablet) formulation [at every visit]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 130 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Histologically confirmed malignant advanced solid tumour, which is refractory to standard therapies (except Group 8 patients who must not be platinum refractory) or for which no suitable effective standard therapy exists

    • Patients must have adequate organ and bone marrow function measured within 7 days prior to administration of study treatment

    • Female patients must have evidence of non-child bearing status: negative urine or serum pregnancy test within 7 days of study treatment for women of child bearing, or postmenopausal status

    Exclusion Criteria:

    • Patients receiving chemotherapy, radiotherapy (except for palliative reasons) or any other anti-cancer therapy within 4 weeks of the last dose prior to study entry. Patients may continue the use of biphosphonates for bone metastases and corticosteroids

    • Patients with symptomatic uncontrolled brain metastases

    • Major surgery within 2 weeks of starting study and patients must have recovered from any effects of any major surgery

    • Patients who are platinum refractory (Group 8 only)

    • Patients with myelodysplastic syndrome/acute myeloid leukaemia (Group 8 only).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Research Site Randwick Australia 2031
    2 Research Site Leuven Belgium 3000
    3 Research Site Bellinzona Switzerland CH-6500
    4 Research Site Edinburgh United Kingdom EH4 2XR
    5 Research Site London United Kingdom NW1 2PG
    6 Research Site Manchester United Kingdom M20 4BX
    7 Research Site Newcastle upon Tyne United Kingdom NE7 7DN
    8 Research Site Northwood United Kingdom HA6 2RN
    9 Research Site Oxford United Kingdom OX3 7LE
    10 Research Site Sutton United Kingdom SM2 5PT

    Sponsors and Collaborators

    • AstraZeneca

    Investigators

    • Study Director: Jane Robertson, BSc, MBCHB, MD, AstraZeneca
    • Principal Investigator: Stan Kaye, Professor, Royal Marsden NHS Foundation Trust

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    AstraZeneca
    ClinicalTrials.gov Identifier:
    NCT00777582
    Other Study ID Numbers:
    • D0810C00024
    First Posted:
    Oct 22, 2008
    Last Update Posted:
    Jun 2, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Keywords provided by AstraZeneca
    Poly (ADP ribose) polymerases
    Homologous Recombination Deficiency (HRD)
    Advanced solid tumours
    Additional relevant MeSH terms:
    Olaparib

    Study Results

    No Results Posted as of Jun 2, 2022